Cary, NC, United States
Cary, NC, United States

Time filter

Source Type

This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP)-modified dual GLP-1/Glucagon receptor agonist, and methods of producing and using the same.


Patent
Biologics | Date: 2017-02-15

A polypeptide consisting of a coagulation factor and one to five human chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein the sequence of said CTPs comprises the first 10 amino acids of SEQ ID NO: 4 (i.e., the amino acid sequence SSSSKAPPPS), and optionally, a signal peptide attached to the amino terminus of said coagulation factor. Pharmaceutical compositions comprising the polypeptides and medical uses thereof are also disclosed.


The use of an oncolytic virus and an aurora kinase inhibitor in the treatment of cancer is disclosed.


The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IIp) and compositions thereof from blood.


The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.


Patent
Dartmouth College and Biologics | Date: 2017-03-22

Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.


Patent
Biologics | Date: 2017-08-09

A polypeptide comprising a biological activity, said polypeptide comprising a peptide of interest, a single chorionic gonadotropin carboxy terminal peptide attached to the amino terminus of said peptide, two chorionic gonadotropin carboxy terminal peptides attached to the carboxy terminus of said peptide, wherein said polypeptide is the mature polypeptide wherein the signal peptide has been cleaved from the precursor protein, wherein the amino acid sequence of said precursor protein is set forth in SEQ ID NO: 39, and wherein said peptide of interest is hGH.


Concentrated, low-viscosity, low- volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high- molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.


Patent
Biologics | Date: 2017-08-02

Mineral-based composition and methods of use thereof in preventing skin damages, such as in subjects exposed to radiation, are provided.


Patent
Biologics | Date: 2017-07-26

The present disclosure relates to developing cell lines where specific biological pathways are modified, particularly by modifications in the enzymes of the cell. The present disclosure develops protein expression systems wherein specific modification of glycan chain of the protein is achieved, which produces non-fucosylated proteins, including non-fucosylated antibodies. The non-fucosylated proteins are used in developing therapeutic monoclonal antibodies and biomarkers, and in diagnosis and prognosis of various diseases. The present disclosure employs the Transcription Activator like Effector Nuclease (TALEN) technology for inactivating fucosylation in a cell.

Loading Biologics collaborators
Loading Biologics collaborators